Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase II Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients with Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase II study of the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.